NAPROSYN GEL ® is a drug based on Naproxen
THERAPEUTIC GROUP: Non-steroidal anti-inflammatory drugs for topical use
Indications NAPROSYN GEL ® Naproxen
SYNFELX ® is used in the treatment of painful inflammatory conditions affecting various organs and systems.
Mechanism of action NAPROSYN GEL ® Naproxen
SYNFELX ® is commonly used with success in clinical practice, for the treatment of painful conditions on an inflammatory basis, given the particular pharmacokinetic properties of sodium Naproxen, which allow the aforementioned active ingredient, following oral intake, to be rapidly absorbed by the mucosa. intestinal, reaching maximum plasma concentrations in about 90 minutes.
In the bloodstream, Naproxen, bound to plasma proteins, is effectively distributed among the various organs and systems, where, by reversibly binding some enzymes known as cyclooxygenases, it inhibits the production of prostaglandins.
Prostaglandins, whose concentrations tend to increase significantly during inflammatory processes of various kinds, thanks to the vasopermeabilizing, chemotactic action against inflammatory cells and antiplatelet agents, support the inflammatory process active in the area of damage.
Consequently, the intake of active ingredients such as Naproxen, or non-steroidal anti-inflammatory drugs, by stopping the production of prostaglandins guarantees:
- A sensitive anti-inflammatory action, reducing damaging events to the tissue;
- A "pain-relieving action, inhibiting the production of pain mediators, active on the peripheral nociceptive endings;
- A modest antipyretic action, reducing the production of cytokines such as IL1 and prostaglandins such as PGE2 capable of acting at the hypothalamic level, triggering the febrile mechanisms.
At the end of its action, Naproxen, following a hepatic metabolism, is excreted in the form of inactive catabolites mainly through the urine.
Studies carried out and clinical efficacy
1. NAPROXEN IN THE TREATMENT OF ACCIDENTS
Am J Med. 1988 May 20; 84 (5A): 45-9.
Piroxicam and naproxen in acute sports injuries.
Lereim P, Gabor I.
Study that demonstrates the efficacy of Naproxen as well as of piroxicam in the treatment of painful states associated with joint injuries in athletes, up to the complete remission of symptoms after a few days of treatment.
2. NAPROXENE IN ORTHOPEDIC PRACTICE
Orthopedics. 1988 Apr; 11: 575-80.
Naproxen sodium: comparative efficacy and tolerability of two dosages for pain after joint surgery.
Goldberg MA, McLaughlin GE, Kieffer DA, Stern L, Hirose H, Akeson W, Hewson GF Jr.
Work that demonstrates the efficacy of Naproxen sodium in the treatment of moderate and severe pain following joint surgery of the hip, shoulder and knee.
3. NAPROXENE IN POST-OPERATIVE PAIN
Cochrane Database Syst Rev. 2004 Oct 18;: CD004234.
Single dose oral naproxen and naproxen sodium for acute postoperative pain.
Mason L, Edwards JE, Moore RA, McQuay HJ.
Very interesting clinical trial that demonstrates how Naproxen, especially when taken orally, can be effective in reducing acute postoperative pain, without clinically relevant side effects
Method of use and dosage
SYNFELX ®
Hard capsules of 275 mg of Naproxen sodium;
Naproxen sodium coated tablets 550 mg;
Suppositories of 275-550 mg of sodium Naproxen;
Naproxen sodium granules for oral suspension of 550 mg.
The intake of SYNFELX ® should be supervised by your doctor, who should establish the correct dosage schedule based on the physio-pathological characteristics of the patient, taking care to further adapt it in elderly patients or patients with kidney and liver diseases.
Generally, it is recommended to take 550 mg of Naproxen sodium every 12 hours, rather than 275 mg of Naproxen sodium every 6-8 hours.
In any case, it would be advisable to start therapy with the lowest effective dose, in order to reduce the incidence of unwanted side effects as much as possible.
Warnings NAPROSYN GEL ® Naproxen
SYNFELX ® therapy should be supervised by your doctor in order to avoid the onset of serious side effects and at the same time maintain maximum therapeutic efficacy.
The treatment should be understood as short-term symptomatic therapy, necessary to ensure a remission of the painful symptoms in progress.
Particular attention should be paid to patients suffering from gastrointestinal, cardiovascular, hepatic and renal diseases, in which the intake of Naproxen could determine the worsening of the clinical picture in progress rather than the onset of new side effects.
In this regard, the onset of unexpected side effects should therefore alarm the patient, who, after consulting his doctor, should consider the possibility of stopping the treatment.
SYNFELX ® contains lactose therefore its intake is not recommended in patients with lactase enzyme deficiency, glucose-galactose malabsorption syndrome and galactose intolerance.
PREGNANCY AND BREASTFEEDING
The use of SYNFELX ® is contraindicated during pregnancy, given the numerous studies that demonstrate the important toxic effects of non-steroidal anti-inflammatory drugs on the health of the fetus.
More precisely, the scientific literature reports several cases of cardiorespiratory malformations and unwanted abortions, following the intake of high doses of NSAIDs during gestation, and in particular in the last trimester of pregnancy.
This contraindication is also supported by the effects on the pregnant woman, subject to an increased risk of bleeding as well as complications during childbirth.
Interactions
Although pharmacological studies show numerous possible interactions between non-steroidal anti-inflammatory drugs such as Naproxen and other active ingredients, from a clinical point of view, those of greatest concern are with:
- Oral anticoagulants and serotonin reuptake inhibitors, responsible for the increased risk of bleeding;
- Diuretics, ACE inhibitors, angiotensin II antagonists, methotrexate and cyclosporine, for the increase of the hepatotoxic and nephrotoxic effects of Naproxen;
- Non-steroidal anti-inflammatory and cortisone drugs, given the increased risk of irritating and histological damage to the gastrointestinal mucosa;
- Antibiotics, responsible for pharmacokinetic alterations and relative therapeutic efficacy;
- Sulfonylureas, for disorders of glucose metabolism, given the potential hypoglycemic effect induced by NSAIDs.
Contraindications NAPROSYN GEL ® Naproxen
The intake of SYNFELX ® is contraindicated in case of hypersensitivity to the active substance or to one of its excipients, hypersensitivity to acetylsalicylic acid and other analgesics, nasal polyposis, asthma, bronchospasm, angioedema, peptic ulcer, history of intestinal bleeding, colitis ulcer disease, Crohn's disease or previous history of the same conditions, cerebrovascular bleeding, haemorrhagic diathesis or concomitant anticoagulant therapy, renal insufficiency and hepatic insufficiency.
Undesirable Effects - Side Effects
Treatment with Naproxen, as well as that with other non-steroidal anti-inflammatory drugs, is often related to the onset of undesirable effects, the incidence and severity of which tend to increase with increasing doses and duration of therapy.
Although the intake of SYNFELX ®, according to the prescribed dosage schedules, tends to minimize the onset of adverse reactions, it is necessary to remember how Naproxen-based therapy can determine the appearance of symptoms:
- Gastrointestinal symptoms such as nausea, vomiting, diarrhea, constipation, gastritis, and in the most serious cases ulcers with possible erosions and bleeding;
- Nervousness such as headache, dizziness and rarely sleepiness;
- Dermatological such as itching, skin rash, eczema, urticaria and bullous reactions, even severe;
- Cardiovascular with hypotension, hypertension and increased cardio and cerebrovascular accidents;
- Sensory problems with sight and hearing;
- Respirators such as asthma, dyspnoea, pneumonia and edema;
- Renal and hepatic, with impairment of the functionality of both organs and related systems.
Note
NAPROSYN GEL ® can be sold without a prescription.
The information on NAPROSYN GEL ® Naproxen published on this page may be out of date or incomplete. For a correct use of this information, see the Disclaimer and useful information page.
